| Lung Non-Small Cell Carcinoma17 |
|---|
| MET Amplification OR MET Exon 14 Skipping Mutation | (prognostic) | Prognostic | B | Supports Poor Outcome | 5 | submitted | EID11387A study of 687 patients with non-small-cell lung cancer were tested for MET exon splicing mutation or MET amplification. Univariable analysis showed that shorter overall disease-specific survival was … (full text at CIViC) PMID 26847053 · Tong et al., 2016 · Open in CIViC | civic |
| MET Amplification OR MET Exon 14 Skipping Mutation | Capmatinib | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID11458Twenty patients with advanced non-small-cell lung cancer (NSCLC) with MET amplification or MET exon 14 skipping mutations were enrolled in this phase II clinical trial. All patients first received cri… (full text at CIViC) PMID 33545388 · Dagogo-Jack et al., 2021 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Capmatinib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID8847In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations were assigned to cohorts based on prior treatment and type of MET alteration. A total of 97 patients, fr… (full text at CIViC) PMID 32877583 · Wolf et al., 2020 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Capmatinib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7795An 82 year old with metastatic NSCLC had disease recurrence 39 months after complete surgical resection. Genomic profiling of the primary resection harbored a MET variant c.3028G>C, as well as a frame… (full text at CIViC) PMID 25971938 · Frampton et al., 2015 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Capmatinib | Predictive | C | Supports Adverse Response | 2 | submitted | EID11409A 68-year old male (former smoker: 50 pack-years) was diagnosed with stage IV lung adenocarcinoma with pleural disseminations and positive intra-abdominal lymph node. Analysis of tumor tissue showed a… (full text at CIViC) PMID 33347701 · Kanemura et al., 2021 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Capmatinib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12866H596 cells harboring mutant c-MET due to exon 14 deletion were shown to be sensitive to capmatinib (INCB28060) inhibiting phospho-c-MET in in vitro ELISA studies. IC50s were 0.4 nM for H596 cells. Cap… (full text at CIViC) PMID 21918175 · Liu et al., 2011 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Crizotinib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7640Patients with non-small cell lung carcinoma harboring MET alterations were treated with crizotinib.
MET amplification was defined as more than or equal to 6 copies.
The response rate at 2 cycles in pa… (full text at CIViC) PMID 31584608 · Moro-Sibilot et al., 2019 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Crizotinib | Predictive | B | Supports Sensitivity Response | 1 | accepted | EID7642Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the phase I PROFILE 1001 study (NCT00585195) and received crizotinib. Responses were assessed. By data-cut off 18 pts with … (full text at CIViC) Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Crizotinib | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID11416780 patients with lung cancer were included in this retrospective study. 16 patients with MET mutations were identified, consisting of 7 with MET exon 14 skipping mutations. Analysis of survival of th… (full text at CIViC) PMID 35679833 · Shalata et al., 2022 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Crizotinib | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID7643In this case Report, a 67-year old female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of c… (full text at CIViC) PMID 26892698 · Mahjoubi et al., 2016 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Tepotinib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID8848In this open-label phase 2 trial, MET inhibitor tepotinib was administered to patients with non-small cell lung cancer and MET exon 14 skipping mutation found in either liquid and/or tissue biopsy. A … (full text at CIViC) PMID 32469185 · Paik et al., 2020 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Tepotinib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11766In the VISION phase 2 trial (NCT02864992), 313 patients with advanced, metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations were treated with 500 mg/kg tepotinib daily. In t… (full text at CIViC) PMID 37270698 · Mazieres et al., 2023 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Tepotinib | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID7272In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib.
9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD.… (full text at CIViC) Open in CIViC | civic |
| MET Exon 14 Skipping Mutation | Tepotinib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11415An 84-year old man (smoker: 62-pack-years) was diagnosed with stage IVB non-small-cell lung cancer (NSCLC) and was started on carboplatin and nab-paclitaxel. After the tumor progressed, the patient wa… (full text at CIViC) PMID 35383870 · Tanaka et al., 2022 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation AND CD274 Overexpression | Pembrolizumab | Predictive | B | Does Not Support Sensitivity Response | 2 | submitted | EID11419Twenty-four patients with MET exon 14 skipping mutation and PD-L1 expression >50% were included in this retrospective study. Median overall survival of these patients was 12.1 months (CI: 9.1 - NR) an… (full text at CIViC) PMID 36210290 · Guisier et al., 2022 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation AND MET D1228N | Crizotinib | Predictive | C | Supports Resistance | 2 | submitted | EID11403An 83-year old male (smoker) was diagnosed with adenocarcinoma of right upper lung. Next-generation sequencing (NGS) analysis found MET exon 14 skipping mutation and MET C526F mutation and the patient… (full text at CIViC) PMID 31055074 · Jin et al., 2019 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation OR MET Overexpression | AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID1142238 patients with locally advanced or metastatic non-small-cell lung cancer were divided into two groups, Part A had c-MET overexpression and Part B had MET exon 14 skipping mutation. Part A was given … (full text at CIViC) PMID 37041472 · Hu et al., 2023 · Open in CIViC | civic |